- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01385631
Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction. (OCTIVUS)
The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound.
The purpose of the study is to examine the effect of the cholesterol lowering agent Ezetimibe when used in addition to optimal treatment with Atorvastatin in patients with acute ST-Elevation Myocardial Infarction (STEMI) who have not been in prior statin therapy.
An area with arteriosclerosis not demanding intervention in a coronary vessel other than the infarct related is used as measuring point and is examined at time of the infarction and after 12 month using intravascular ultrasound and optical coherence tomography. At the same time the same techniques are used to examine the implanted stent.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Optical coherence tomography (OCT) and intravascular ultrasound (IVUS) with tissue characterization (IVUS-TC) are relatively new expansions to intravascular assessments, and has the capacity to assess plaque composition and, potentially, to identify vulnerable plaques. One of the mechanisms by which statins improve patient outcomes may be by changing the composition of a "vulnerable" plaque. The main effect is believed to rely on a lowering of LDL-c. The question is whether a further reduction of LDL by adding ezetimibe to optimal cholesterol lowering therapy using statins may result in further plaque stabilization or reduction. This is the hypothesis of the current study.
100 patients are randomized to Ezetimibe 10 mg per day or placebo. All patients are treated with Atorvastatin 80 mg. OCT and IVUS are performed at inclusion (typically the day after Primary PCI) and again at follow-up after 12 month.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Odense C, Denemarken, 5000
- Department of Cardiology, Odense University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ST segment elevation acute myocardial infarction
- 20% < angiographic diameter stenosis < 50% on a not previously revascularized native coronary artery
- Statin naïve
- In fertile women: Ongoing contraception with IUD or hormonal contraception.
Exclusion Criteria:
- Pharmacologic lipid lowering treatment before index hospitalization
- Atrial fibrillation, not well rate-controlled
- Ventricle frequency variation with more than a factor 2 over 1 minute
- Unconscious patients
- History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins) including Atorvastatin.
- Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have a positive serum pregnancy test (a serum-human chorionic gonadotrophin [Beta-HCG] analysis)
- History of malignancy (unless a documented disease free period exceeding 5-years is present) with the exception of basal cell or squamous cell carcinoma of the skin. Women with a history of cervical dysplasia would be permitted to enter the study provided they had 3 consecutive clear Papanicolaou (Pap) smears
- Uncontrolled hypothyroidism (TSH > 1.5xULN)
- Abnormal LFT's
- History of alcohol or drug abuse within the last 5 years (this may affect compliance)
- Current active liver disease (ALT/SGPT >2xULN or severe hepatic impairment (to protect patient safety as directed on the labels of currently approved statins)
- Unexplained creatine kinase (CK > 3xULN) (To protect patient safety) (will be increased at baseline because of acute ST segment elevation myocardial infarction a few days before enrolment)
- Serum creatinine >176mmol/L (2.0mg/dL) (unless the protocol specifically aims to investigate a chronic renal disease population)
- Participation in another investigational drug study less than 4 weeks before enrolment in the study, or according to subjects local ethics committee requirements where a larger period is stipulated (to avoid potential misinterpretation of overlapping adverse events)
- Treatments with cyclosporine
- Treatment with gemfibrozil
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Atorvastatin plus Placebo
50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
|
100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
Andere namen:
|
Experimenteel: Atorvastatin plus Ezetimibe
100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
|
100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Plaque volume and composition in a non-significant coronary plaque
Tijdsspanne: After 12 months of follow-up
|
Plaque volume assessed by intravascular ultrasound and Optical Coherence Tomography
|
After 12 months of follow-up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change in plaque-composition (measured with Tissue Characterization) in a 10 mm segment of a native coronary vessel with a non-significant stenosis where plaque-volume at baseline is greatest.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Change in percent of the plaque volume in the native coronary vessel with a non-significant stenosis.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Change in percent of the plaque volume in the 10 mm segment of a native coronary vessel with a non-significant lesion where plaque volume at baseline is greatest.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Change in absolute numbers of the plaque volume in the 10 mm segment of a native coronary vessel with a non-significant lesion where plaque volume at baseline is greatest.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Change in percent of the plaque burden in the 10 mm segment of a native coronary vessel with a non-significant lesion where plaque volume at baseline is greatest.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Change in percent of the plaque burden in a native coronary vessel with a non-significant lesion.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Incomplete stent apposition.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Edge response in stented segment.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Stent expansion.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Evaluation of the OCT-technique in clinical use compared to IVUS.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Evaluation of the Resolute stents effect on neointima growth and apposition.
Tijdsspanne: After 12 months of follow-up
|
After 12 months of follow-up
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mikkel Hougaard, MD, Department of Cardiology, Odense University Hospital
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- OKT
- Optische coherentietomografie
- Gerandomiseerde proef
- Enzymremmers
- Atorvastatine
- IVUS
- Farmacologische acties
- Therapeutische toepassingen
- Ezetimibe
- Intravasculaire echografie
- Hydroxymethylglutaryl-CoA-reductaseremmers
- Moleculaire mechanismen van farmacologische werking
- ST-segment elevatie myocardinfarct
- Hypolipidemische middelen
- Vetregulerende middelen
Aanvullende relevante MeSH-voorwaarden
- Ischemie
- Pathologische processen
- Necrose
- Myocardiale ischemie
- Hartziekten
- Hart-en vaatziekten
- Vaatziekten
- Myocardinfarct
- Infarct
- ST-elevatie myocardinfarct
- Moleculaire mechanismen van farmacologische werking
- Antimetabolieten
- Middelen tegen cholesterol
- Hypolipidemische middelen
- Vetregulerende middelen
- Ezetimibe
Andere studie-ID-nummers
- OUH-OCTIVUS
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op ST-segment elevatie myocardinfarct
-
Yonsei UniversityCardioVascular Research Foundation, KoreaVoltooid
-
Uppsala UniversityLund UniversityVoltooidST-segment elevatie myocardinfarct | Niet-ST-segment elevatie myocardinfarctZweden
-
University College, LondonVoltooidST-segment elevatie myocardinfarct (STEMI)Mauritius
-
RenJi HospitalNog niet aan het wervenST-segment elevatie myocardinfarct (STEMI)
-
Peking University Third HospitalNog niet aan het wervenST-segment elevatie myocardinfarct (STEMI)
-
The First Affiliated Hospital with Nanjing Medical...Voltooid
-
Samsung Medical CenterRainMed Medical; Shanghai Institute of Cardiovascular DiseasesActief, niet wervendST-segment elevatie myocardinfarct (STEMI)Verenigde Staten, China
-
Renmin Hospital of Wuhan UniversityThe First Affiliated Hospital of Dalian Medical University; Jiangxi Provincial... en andere medewerkersVoltooid
-
Assiut UniversityNog niet aan het wervenST-segment elevatie myocardinfarct (STEMI)
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten